Total Payments
$8,060
2024 Payments
$1,324
Companies
59
Transactions
494
Medicare Patients
35,777
Medicare Billing
$14.9M
Payment Breakdown by Category
Food & Beverage$7,452 (92.5%)
Education$607.67 (7.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,452 | 480 | 92.5% |
| Education | $607.67 | 14 | 7.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,247 | 80 | $0 (2024) |
| PFIZER INC. | $761.04 | 74 | $0 (2024) |
| Janssen Biotech, Inc. | $685.05 | 32 | $0 (2024) |
| Genentech USA, Inc. | $637.94 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $394.20 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $291.88 | 21 | $0 (2024) |
| Celgene Corporation | $257.92 | 13 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $245.18 | 13 | $0 (2023) |
| Astellas Pharma US Inc | $227.45 | 11 | $0 (2024) |
| ARRAY BIOPHARMA INC | $225.74 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,324 | 62 | PFIZER INC. ($181.91) |
| 2023 | $1,426 | 68 | Janssen Biotech, Inc. ($276.94) |
| 2022 | $1,059 | 59 | Genentech USA, Inc. ($177.93) |
| 2021 | $178.31 | 7 | Exelixis Inc. ($82.40) |
| 2020 | $212.05 | 17 | Novartis Pharmaceuticals Corporation ($38.03) |
| 2019 | $1,040 | 68 | PFIZER INC. ($166.25) |
| 2018 | $1,392 | 104 | Novartis Pharmaceuticals Corporation ($284.41) |
| 2017 | $1,428 | 109 | Novartis Pharmaceuticals Corporation ($288.44) |
All Payment Transactions
494 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $77.97 | General |
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $0.58 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Oncology | ||||||
| 10/30/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: HEMATOLOGY | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $26.14 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 09/27/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 09/23/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: Hematology | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $12.25 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Oncology | ||||||
| 09/02/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/30/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.97 | General |
| Category: Hematology | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Oncology | ||||||
| 08/27/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.07 | General |
| Category: Hematology | ||||||
| 08/21/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 08/16/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.29 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 65 | 6,080 | 354,016 | $12.0M | $3.4M |
| 2022 | 89 | 8,675 | 366,191 | $13.2M | $3.8M |
| 2021 | 100 | 10,281 | 416,297 | $11.9M | $3.4M |
| 2020 | 105 | 10,741 | 496,292 | $13.7M | $4.2M |
Total Patients
35,777
Total Services
1,632,796
Medicare Billing
$14.9M
Procedure Codes
359
All Medicare Procedures & Services
359 procedure records from CMS Medicare Utilization — Page 1 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 26,400 | $3.6M | $1.1M | 31.7% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 37,220 | $2.7M | $881,454 | 32.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 77 | 10,620 | $541,620 | $194,814 | 36.0% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 11 | 2,880 | $668,160 | $183,255 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 650 | 1,825 | $618,675 | $174,651 | 28.2% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 11 | 3,432 | $398,112 | $90,197 | 22.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 151 | 906 | $342,468 | $88,212 | 25.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 45 | 14,220 | $327,060 | $82,070 | 25.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 35 | 4,700 | $267,900 | $79,055 | 29.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 104 | 118,830 | $475,320 | $46,523 | 9.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 482 | 632 | $151,048 | $40,153 | 26.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 35 | 252 | $141,624 | $33,704 | 23.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 953 | 3,830 | $34,470 | $32,172 | 93.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 42 | 22,880 | $114,400 | $31,493 | 27.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 916 | 4,094 | $118,726 | $31,117 | 26.2% |
| J1954 | Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | Office | 2023 | 20 | 93 | $112,530 | $28,337 | 25.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 166 | 564 | $106,596 | $26,919 | 25.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 21,750 | $65,250 | $18,966 | 29.1% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 11 | 5,360 | $53,600 | $17,345 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 141 | 141 | $63,873 | $16,926 | 26.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 98 | 116 | $64,496 | $15,803 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 257 | 1,436 | $99,084 | $14,821 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 101 | $47,874 | $14,016 | 29.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 51 | 265 | $47,170 | $12,938 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 77 | 77 | $45,045 | $12,519 | 27.8% |
About Dr. Paul Dodd, MD
Dr. Paul Dodd, MD is a Hematology healthcare provider based in Ormond Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1538165113.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Dodd, MD has received a total of $8,060 in payments from pharmaceutical and medical device companies, with $1,324 received in 2024. These payments were reported across 494 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($7,452).
As a Medicare-enrolled provider, Dodd has provided services to 35,777 Medicare beneficiaries, totaling 1,632,796 services with total Medicare billing of $14.9M. Data is available for 4 years (2020–2023), covering 359 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Ormond Beach, FL
- Active Since 06/28/2005
- Last Updated 05/02/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1538165113
Products in Payments
- IMBRUVICA (Drug) $369.64
- PROMACTA (Drug) $353.88
- KISQALI (Drug) $313.30
- KEYTRUDA (Biological) $275.78
- IBRANCE (Drug) $270.86
- XTANDI (Drug) $263.56
- OPDIVO (Biological) $257.61
- DARZALEX (Biological) $227.10
- JEVTANA (Drug) $161.91
- MEKINIST (Drug) $136.19
- Kyprolis (Biological) $134.47
- JADENU (Drug) $131.36
- Imbruvica (Drug) $117.41
- Trodelvy (Drug) $115.58
- VENCLEXTA (Biological) $114.69
- JAKAFI (Drug) $114.22
- Avastin (Biological) $111.65
- REBLOZYL (Biological) $110.11
- XALKORI (Drug) $105.03
- ERLEADA (Drug) $99.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.